Aegerion Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Aegerion Pharmaceuticals's estimated annual revenue is currently $300M per year.
- Aegerion Pharmaceuticals's estimated revenue per employee is $10,344,828
- Aegerion Pharmaceuticals's total funding is $63.7M.
Employee Data
- Aegerion Pharmaceuticals has 29 Employees.
- Aegerion Pharmaceuticals grew their employee count by -9% last year.
Aegerion Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|
Aegerion Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's initial focus will be on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase II testing. Aegerion is also in active discussions regarding in-licensing opportunities in the cardiovascular or metabolic therapeutic areas. Incorporated in February 2005 and headquartered in Bridgewater, New Jersey, Aegerion Pharmaceuticals is a specialty pharmaceutical company focusing on the development and commercialization of promising therapeutics to treat cardiovascular / metabolic disease. Our initial emphasis will be on hyperlipidemia. Our lead products are microsomal triglyceride transfer protein (MTP) inhibitors that have demonstrated significant LDL lowering activity in man.
keywords:N/A
$63.7M
Total Funding
29
Number of Employees
$300M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aegerion Pharmaceuticals News
Law360 (April 19, 2022, 12:50 PM EDT) -- A former Aegerion Pharmaceuticals Inc. salesman convicted of fraud should repay $1.6 million to three insurers he...
Before joining Casebia, he held senior finance positions at Aegerion Pharmaceuticals, Inc., Systagenix Wound Management Ltd.,...
Aegerion Pharmaceuticals, Inc., Catabasis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Novartis AG, uniQure N.V.. Report overview: * The...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 29 | 38% | $35M |
#2 | $2.9M | 29 | N/A | N/A |
#3 | $3.5M | 29 | 7% | N/A |
#4 | $4.5M | 29 | 7% | N/A |
#5 | $3M | 29 | -3% | N/A |